KM Research Hub
← 返回论文库
部分完成 入排:符合 图源:可得 入排置信度 0.98

Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5-year update of the CinClare trial.

Zhen Zhang, Xinchen Sun, Anwen Liu, Yaqun Zhu, Tao Zhang, Luying Liu, Jianhui Jia, Shisheng Tan, Junxin Wu, Xin Wang, Juying Zhou, Jialin Yang, Chen Zhang, Hongyan Zhang, Xinjia He, Gang Cai, Chengyi Huang, Fan Xia, Juefeng Wan, Hui Zhang, Lijun Shen, Ling Wang, Wei Zhang, Sanjun Cai, Ji Zhu

Cancer Commun (Lond) 45(11) 1417-1430

PMID40899645
PMCIDPMC12629858
DOI10.1002/cac2.70058
发表日期2025-09-03
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: The optimal regimen and chemotherapy intensity are still under investigation for neoadjuvant treatment of locally advanced rectal cancer (LARC). The CinClare trial has demonstrated improved pathologic complete response (pCR) with the addition of irinotecan to neoadjuvant chemoradiotherapy (CRT) guided by uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotype in LARC. Here, we report the 5-year follow-up outcomes of the CinClare study. METHODS: From November 2015 to December 2017, this randomized, open-label, multicenter, phase III trial enrolled 360 patients with LARC and assigned them in a 1:1 ratio to CapIriRT (radiation with capecitabine combined with irinotecan followed by irinotecan and capecitabine) or CapRT (radiation with concurrent capecitabine followed by oxaliplatin and capecitabine). Irinotecan dosing was guided by UGT1A1 genotype (80 mg/m2 for *1/*1 and 65 mg/m2 for *1/*28). The endpoints, including local control (LC), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS), were analyzed using the log-rank test, Cox proportional hazards regression and restricted mean survival time (RMST) test at the data cut-off date of June 2023. RESULTS: With a median follow-up of 60 months, the CapIriRT group showed numerically higher 5-year LC (95.6% vs. 93.9%), 5-year DMFS (83.9% vs. 77.9%), 5-year DFS (77.7% vs. 70.6%), and 5-year OS rates (82.9% vs. 76.1%) than the CapRT group. Further RMST test also showed a statistically significant difference in DFS (P < 0.05) and a borderline difference in OS (P = 0.050). Among the UGT1A1 *1/*1 population, the CapIriRT group had significantly improved 5-year rates of DMFS, DFS, and OS (all P < 0.05). Patients achieving pCR also had significantly longer DFS and OS compared to non-pCR patients (P < 0.05). CONCLUSIONS: The addition of irinotecan guided by UGT1A1 genotype to a standard capecitabine-based scheme brings clinical benefits with improved LC, DMFS, DFS, and OS. Patients with the UGT1A1 *1/*1 genotype derived notable benefit from irinotecan, with improved survival outcomes. Achievement of pCR is crucial as it is associated with improved long-term survival. These findings support the integration of genomic testing into clinical practice to achieve a personalized irinotecan dosing regimen, which can optimize efficacy and safety. TRIAL REGISTRATION: ClinicalTrials.gov (NCT02605265).

KM 提取结果

4 个 Figure · 24 个 KM 面板

进入结果中心
KM Figure4 个面板

FIGURE 1

FIGURE 1 Long‐term survival outcomes in the mITT population ( n = 356). (A) Kaplan‐Meier curve of LC. The 5‐year LC rates were 95.6% and 93.9% in the CapIriRT and CapRT groups, respectively. (B) Kaplan‐Meier curve of DMFS. The 5‐year DMFS rates were 83.9% and 77.9% in the CapIriRT and CapRT groups, respectively. (C) Kaplan‐Meier curve of DFS. The 5‐year DFS rates were 77.7% and 70.6% in the CapIriRT and CapRT groups, respectively. (D) Kaplan‐Meier curve of OS. The 5‐year OS rates were 82.9% and 76.1% in the CapIriRT and CapRT groups, respectively. Abbreviations: CI, confidence interval; DFS, disease‐free survival; DMFS, distant metastasis‐free survival; HR, hazard ratio; LC, local control; mITT, modified intent‐to‐treat; OS, overall survival.

_A_

LC

FIGURE 1 · Panel _A_

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel _A_ 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
_B_

DMFS

FIGURE 1 · Panel _B_

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel _B_ 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
_C_

DFS

FIGURE 1 · Panel _C_

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel _C_ 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
_D_

OS

FIGURE 1 · Panel _D_

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel _D_ 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure8 个面板

FIGURE 3

FIGURE 3 Long‐term survival outcomes stratified by UGT1A1 genotype. (A‐D) Kaplan‐Meier curves for LC, DMFS, DFS and OS of UGT1A1 *1/*1 subgroup, respectively. (E‐H) Kaplan‐Meier curves for LC, DMFS, DFS and OS of UGT1A1 *1/*28 subgroup, respectively. In the UGT1A1 *1/*1 subgroup, patients who received CapIriRT showed improved DMFS, DFS, and OS ( p < 0.05) compared to those who received CapRT, as well as a numerical advantage in LC. In the UGT1A1 *1/*28 genotype subgroup, no substantial differences were observed in LC, DMFS, DFS, and OS. Abbreviations: DFS, disease‐free survival; DMFS, distant metastasis‐free survival; LC, local control; OS, overall survival; UGT1A1, uridine diphosphate glucuronosyltransferase 1A1.

A

Local control probability

FIGURE 3 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 1:flat topline artifact曲线 2:extreme jump曲线 2:off origin start
查看结果
B

DMFS probability

FIGURE 3 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

DFS probability

FIGURE 3 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D

OS probability

FIGURE 3 · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
E

Local control probability

FIGURE 3 · Panel E

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel E 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
F

DMFS probability

FIGURE 3 · Panel F

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel F 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
G

DFS probability

FIGURE 3 · Panel G

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel G 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
H

OS probability

FIGURE 3 · Panel H

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel H 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure4 个面板

FIGURE 4

FIGURE 4 Survival outcomes stratified by pCR status in 311 patients who had undergone surgery in the mITT population. (A) Kaplan‐Meier curve of LC. (B) Kaplan‐Meier curve of DMFS. (C) Kaplan‐Meier curve of DFS. (D) Kaplan‐Meier curve of OS. In the mITT population, patients achieving pCR had longer DFS and OS compared to non‐pCR patients, as well as an improved trend for LC and DMFS. Abbreviations: DFS, disease‐free survival; DMFS, distant metastasis‐free survival; LC, local control; OS, overall survival; pCR, pathologic complete response.

A

LC

FIGURE 4 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIGURE 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 2:off origin start
查看结果
B

DMFS

FIGURE 4 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIGURE 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

DFS

FIGURE 4 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 FIGURE 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D

OS

FIGURE 4 · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 FIGURE 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure8 个面板

FIGURE 5

FIGURE 5 Survival outcomes by pCR status in two treatment arms. (A‐D) Kaplan‐Meier curves for LC, DMFS, DFS and OS of the pCR subgroup, respectively. (E‐H) Kaplan‐Meier curves for LC, DMFS, DFS and OS of the non‐pCR subgroup, respectively. Among patients who achieved pCR, outcomes were similar between the CapIriRT and CapRT groups. However, among patients who did not achieve pCR, the CapIriRT group had slightly longer LC, DMFS, and DFS compared to the CapRT group. Abbreviations: DFS, disease‐free survival; DMFS, distant metastasis‐free survival; LC, local control; OS, overall survival; pCR, pathologic complete response.

_A_

local control

FIGURE 5 · Panel _A_

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel _A_ 是同一 FIGURE 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 2:very low support曲线 2:off origin start曲线 2:extreme upward reversal
查看结果
_B_

DMFS

FIGURE 5 · Panel _B_

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel _B_ 是同一 FIGURE 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
_C_

DFS

FIGURE 5 · Panel _C_

failed 待 EXE 对齐 预期 2 条 已提取 0 条

Panel _C_ 是同一 FIGURE 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 0 条曲线 1:extreme jump曲线 1:off origin start曲线 1:extreme upward reversal
No curves extracted
查看结果
_D_

OS

FIGURE 5 · Panel _D_

failed 待 EXE 对齐 预期 2 条 已提取 0 条

Panel _D_ 是同一 FIGURE 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 0 条曲线 1:extreme jump曲线 1:off origin start曲线 1:extreme upward reversal
No curves extracted
查看结果
_E_

local control

FIGURE 5 · Panel _E_

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel _E_ 是同一 FIGURE 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
_F_

DMFS

FIGURE 5 · Panel _F_

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel _F_ 是同一 FIGURE 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
_G_

DFS

FIGURE 5 · Panel _G_

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel _G_ 是同一 FIGURE 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
_H_

OS

FIGURE 5 · Panel _H_

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel _H_ 是同一 FIGURE 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 2FIGURE 2 Subgroup analyses of long‐term outcomes in the mITT population ( n = 356). (A) Forest plot for the hazard ratio of LC in various subgroups of patients. (B) Forest plot for the hazard ratio of DMFS in various subgroups of patients. (C) Forest plot for the hazard ratio of DFS in various subgroups of patients. (D) Forest plot for the hazard ratio of OS in various subgroups of patients. In the UGT1A1 *1/*1 subgroup, patients who received CapIriRT showed improved DMFS, DFS, and OS ( p < 0.05) compared to those who received CapRT, as well as an improved trend in LC. Elevated CEA levels were defined as higher than the respective laboratory thresholds of the participating research centers. AV, anal verge; CEA, carcinoembryonic antigen; CI, confidence interval; DFS, disease‐free survival; DMFS, distant metastasis‐free survival; LC, local control; mITT, modified intent‐to‐treat; OS, overall survival; UGT1A1, uridine diphosphate glucuronosyltransferase 1A1.
非 KM Figure